Relevant bibliographies by topics / Autoimmune arthritis; Ankylosing spondylitis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Autoimmune arthritis; Ankylosing spondylitis'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Autoimmune arthritis; Ankylosing spondylitis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Autoimmune arthritis; Ankylosing spondylitis"

1

Nava, Tiziana. "Physiotherapy rehabilitation in patients with ankylosing spondylitis." Beyond Rheumatology 1, no. 2 (December 20, 2019): 37–46. http://dx.doi.org/10.4081/br.2019.6.

Full text
Abstract:
Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease, it is a form of arthritis characterized by an autoimmune and genetic etiology, included in the group of chronic inflammatory, autoimmune, and diseases. One of the most frequent reasons for the long delay in diagnosis is represented by the AS main symptoms such as: chronic low back pain, very common in this kind of patients, followed by a diagnosis of degenerative disc pathologies, rheumatoid arthritis, and tuberculosis of the spine. Another reason is the quite late appearance of the radiographic signs in the sacroiliac region. The pain symptomatology manifesting itself from the onset of the pathology is the cause of an antalgic response. In this sense an early diagnosis is essential to avoid the establishment of deformities at the level of the spine and of the articular and peri-articular structures. Pharmacological treatment as well as a rehabilitation program are very important and effective in the early phase of the disease. In the most advanced phases, the spine presents an increasing stiffening, with dorsal hyperkyphosis and the abolition of the lumbar lordosis determining the typical postural alterations characteristic of the disease. Early diagnosis and timely delivery to rehabilitation and physiotherapy can significantly reduce disability and complications. The international guidelines and recommendations suggest the pharmacological treatment as well as the rehabilitation and physiotherapy program during the different stages of the disease. In the 2016 update of the ASAS-EULAR recommendations for axial AS, multidisciplinary, non-pharmacological (along with pharmacological) treatment is required to ensure optimal management of the disease. US-based recommendations also suggest the relevance of nonpharmacological therapies, along with recommended patient education, active physiotherapy and regular physical activity.
APA, Harvard, Vancouver, ISO, and other styles
2

Wielinska, Joanna, and Katarzyna Bogunia-Kubik. "miRNAs as potential biomarkers of treatment outcome in rheumatoid arthritis and ankylosing spondylitis." Pharmacogenomics 22, no. 5 (April 2021): 291–301. http://dx.doi.org/10.2217/pgs-2020-0148.

Full text
Abstract:
Common autoimmune, inflammatory rheumatic diseases including rheumatoid arthritis and ankylosing spondylitis can lead to structural and functional disability, an increase in mortality and a decrease in the quality of a patient’s life. To date, the core of available therapy consists of nonsteroidal anti-inflammatory drugs, glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs, like methotrexate. Nowadays, biological therapy including anti-TNF, IL-6 and IL-1 inhibitors, as well as antibodies targeting IL-17 and Janus kinase inhibitors have been found to be helpful in the management of rheumatic conditions. The review provides a summary of the current therapy strategies with a focus on miRNA, which is considered to be a potential biomarker and possible answer to the challenges in the prediction of treatment outcome in patients with rheumatoid arthritis and ankylosing spondylitis.
APA, Harvard, Vancouver, ISO, and other styles
3

Antoniou, Antony N., Izabela Lenart, and David B. Guiliano. "Pathogenicity of Misfolded and Dimeric HLA-B27 Molecules." International Journal of Rheumatology 2011 (2011): 1–9. http://dx.doi.org/10.1155/2011/486856.

Full text
Abstract:
The association between HLA-B27 and the group of autoimmune inflammatory arthritic diseases, the spondyloarthropathies (SpAs) which include ankylosing spondylitis (AS) and Reactive Arthritis (ReA), has been well established and remains the strongest association between any HLA molecule and autoimmune disease. The mechanism behind this striking association remains elusive; however animal model and biochemical data suggest that HLA-B27 misfolding may be key to understanding its association with the SpAs. Recent investigations have focused on the unusual biochemical structures of HLA-B27 and their potential role in SpA pathogenesis. Here we discuss how these unusual biochemical structures may participate in cellular events leading to chronic inflammation and thus disease progression.
APA, Harvard, Vancouver, ISO, and other styles
4

Lai, Benjamin, Chien-Hsiang Wu, and Jenn-Haung Lai. "Activation of c-Jun N-Terminal Kinase, a Potential Therapeutic Target in Autoimmune Arthritis." Cells 9, no. 11 (November 12, 2020): 2466. http://dx.doi.org/10.3390/cells9112466.

Full text
Abstract:
The c-Jun-N-terminal kinase (JNK) is a critical mediator involved in various physiological processes, such as immune responses, and the pathogenesis of various diseases, including autoimmune disorders. JNK is one of the crucial downstream signaling molecules of various immune triggers, mainly proinflammatory cytokines, in autoimmune arthritic conditions, mainly including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. The activation of JNK is regulated in a complex manner by upstream kinases and phosphatases. Noticeably, different subtypes of JNKs behave differentially in immune responses. Furthermore, aside from biologics targeting proinflammatory cytokines, small-molecule inhibitors targeting signaling molecules such as Janus kinases can act as very powerful therapeutics in autoimmune arthritis patients unresponsiveness to conventional synthetic antirheumatic drugs. Nevertheless, despite these encouraging therapies, a population of patients with an inadequate therapeutic response to all currently available medications still remains. These findings identify the critical signaling molecule JNK as an attractive target for investigation of the immunopathogenesis of autoimmune disorders and for consideration as a potential therapeutic target for patients with autoimmune arthritis to achieve better disease control. This review provides a useful overview of the roles of JNK, how JNK is regulated in immunopathogenic responses, and the potential of therapeutically targeting JNK in patients with autoimmune arthritis.
APA, Harvard, Vancouver, ISO, and other styles
5

Stevenson, John. "Inflammatory Arthritis." InnovAiT: Education and inspiration for general practice 2, no. 10 (September 22, 2009): 585–96. http://dx.doi.org/10.1093/innovait/inp149.

Full text
Abstract:
Inflammatory arthritis is an umbrella term used to describe a range of conditions, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and reactive arthritis. These are autoimmune diseases in which joint and systemic features are present in varying degrees between disease processes and individuals. Delayed diagnosis can lead to irreversible joint destruction and dysfunction but a therapeutic revolution has transformed its prognosis. Ever-expanding therapeutic options require GPs to recognize these conditions, manage symptoms and undertake drug monitoring. The costs to individuals, their families and the National Health Service are high. There were 1.9 million GP consultations for inflammatory arthritis in 2000 and nearly 46000 hospital admissions. The challenge in primary care is to recognize an inflammatory arthritis early and refer to secondary care.
APA, Harvard, Vancouver, ISO, and other styles
6

Strouse, Jennifer, Brittney M. Donovan, Munazza Fatima, Ruth Fernandez-Ruiz, Rebecca J. Baer, Nichole Nidey, Chelsey Forbess, et al. "Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study." RMD Open 5, no. 1 (April 2019): e000878. http://dx.doi.org/10.1136/rmdopen-2018-000878.

Full text
Abstract:
ObjectivesAutoimmune rheumatic diseases (ARDs) affect women of childbearing age and have been associated with adverse birth outcomes. The impact of diseases like ankylosing spondylitis and psoriatic arthritis (PsA) on birth outcomes remains less studied to date. Our objective was to evaluate the impact of ARDs on preterm birth (PTB), congenital anomalies, low birth weight (LBW) and small for gestational age (SGA), in a large cohort of women.MethodsWe conducted a propensity score-matched analysis to predict ARD from a retrospective birth cohort of all live, singleton births in California occurring between 2007 and 2012. Data were derived from birth certificate records linked to hospital discharge International Classification of Diseases, ninth revision codes.ResultsWe matched 10 244 women with a recorded ARD diagnosis (rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), antiphospholipid syndrome, PsA); ankylosing spondylitis and juvenile idiopathic arthritis (JIA) to those without an ARD diagnosis. The adjusted OR (aOR) of PTB was increased for women with any ARD (aOR 1.93, 95% CI 1.78 to 2.10) and remained significant for those with RA, SLE, PsA and JIA. The odds of LBW and SGA were also significantly increased among women with an ARD diagnosis. ARDs were not associated with increased odds of congenital anomalies.ConclusionConsistent with prior literature, we found that women with ARDs are more likely to have PTB or deliver an SGA infant. Some reassurance is provided that an increase in congenital anomalies was not found even in this large cohort.
APA, Harvard, Vancouver, ISO, and other styles
7

Amarasekara, Dulshara Sachini, Jiyeon Yu, and Jaerang Rho. "Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases." Journal of Immunology Research 2015 (2015): 1–12. http://dx.doi.org/10.1155/2015/832127.

Full text
Abstract:
Bone remodeling is a lifelong process in vertebrates that relies on the correct balance between bone resorption by osteoclasts and bone formation by osteoblasts. Bone loss and fracture risk are implicated in inflammatory autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, and systemic lupus erythematosus. The network of inflammatory cytokines produced during chronic inflammation induces an uncoupling of bone formation and resorption, resulting in significant bone loss in patients with inflammatory autoimmune diseases. Here, we review and discuss the involvement of the inflammatory cytokine network in the pathophysiological aspects and the therapeutic advances in inflammatory autoimmune diseases.
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Chong, Tianhua Rong, Zheng Li, and Jianxiong Shen. "Noncoding RNAs Involved in the Pathogenesis of Ankylosing Spondylitis." BioMed Research International 2019 (July 7, 2019): 1–8. http://dx.doi.org/10.1155/2019/6920281.

Full text
Abstract:
Ankylosing spondylitis (AS) is a form of arthritis that can lead to fusion of vertebrae and sacroiliac joints following syndesmophyte formation. The etiology of this painful disease remains poorly defined due to its complex genetic background. There are no commonly accepted methods for early diagnosis of AS, nor are there any effective or efficient clinical treatments. Several noncoding RNAs (ncRNAs) have been linked to AS pathogenesis and inflammation via selective binding of their downstream targets. However, major gaps in knowledge remain to be filled before such findings can be translated into clinical treatments for AS. In this review, we outline recent findings that demonstrate essential roles of ncRNAs in AS mediated via multiple signaling pathways such as the Wnt, transforming growth factor-β/bone morphogenetic protein, inflammatory, T-cell prosurvival, and nuclear factor-κB pathways. The summary of these findings provides insight into the molecular mechanisms by which ncRNAs can be targeted for AS diagnosis and the development of therapeutic drugs against a variety of autoimmune diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Tsukazaki, Hiroyuki, and Takashi Kaito. "The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis." International Journal of Molecular Sciences 21, no. 17 (September 3, 2020): 6401. http://dx.doi.org/10.3390/ijms21176401.

Full text
Abstract:
Spondyloarthritis (SpA) is a subset of seronegative rheumatic-related autoimmune diseases that consist of ankylosing spondylitis (AS), psoriatic spondylitis (PsA), reactive spondylitis (re-SpA), inflammatory bowel disease (IBD)-associated spondylitis, and unclassifiable spondylitis. These subsets share clinical phenotypes such as joint inflammation and extra-articular manifestations (uveitis, IBD, and psoriasis [Ps]). Inflammation at the enthesis, where ligaments and tendons attach to bones, characterizes and distinguishes SpA from other types of arthritis. Over the past several years, genetic, experimental, and clinical studies have accumulated evidence showing that the IL-23/IL-17 axis plays a critical role in the pathogenesis of SpA. These discoveries include genetic association and the identification of IL-23- and IL-17-producing cells in the tissue of mouse models and human patients. In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23/IL-17 pathway and examine the recent clinical studies of biological agents targeting IL-23 and IL-17 in the treatment of SpA.
APA, Harvard, Vancouver, ISO, and other styles
10

Granata, Guido, Dario Didona, Giuseppina Stifano, Aldo Feola, and Massimo Granata. "Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature." Case Reports in Medicine 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/294041.

Full text
Abstract:
Macrophage activation syndrome (MAS) is a potentially fatal condition. It belongs to the hemophagocytic lymphohistiocytosis group of diseases. In adults, MAS is rarely associated with systemic lupus erythematosus, but it also arises as complication of several systemic autoimmune disorders, like ankylosing spondylitis, rheumatoid arthritis, and adult-onset Still’s disease. Several treatment options for MAS have been reported in the literature, including a therapeutic regimen of etoposide, dexamethasone, and cyclosporine. Here we report a case of 42-year-old woman in whom MAS occurred as onset of systemic lupus erythematosus.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Autoimmune arthritis; Ankylosing spondylitis"

1

Chan, Vera Sau Fong. "A transgenic mouse system to study the role of cytotoxic T lymphocytes in autoimmune arthritis." Thesis, University of Oxford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.267924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fielder, Mark David. "Molecular studies in ankylosing spondylitis and rheumatoid arthritis." Thesis, King's College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338691.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jones, Cheryl. "The economics of presenteeism in the context of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis." Thesis, University of Manchester, 2018. https://www.research.manchester.ac.uk/portal/en/theses/the-economics-of-presenteeism-in-the-context-of-rheumatoid-arthritis-ankylosing-spondylitis-and-psoriatic-arthritis(8215e79a-925e-4664-9a3c-3fd42d643528).html.

Full text
Abstract:
Background: Presenteeism is an economic concept that is difficult to identify, measure, and value. Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are three chronic auto-immune conditions that increase levels of presenteeism. Workplace interventions (WPIs) help individuals to manage their health condition at work. Existing methods used to quantify the impact of presenteeism are unable to adequately inform the employer of the productive benefits of WPIs. The overall aim of this thesis was to appraise current methods used to quantify presenteeism and to develop methods to value the impact of presenteeism suitable for use in economic evaluations (EE) of WPIs. Methods: Two systematic reviews were conducted: 1) to assess the extent to which self-report measure of presenteeism were underpinned by economic theory; and 2) to explore if, and how, productivity was quantified and included in EE of WPIs for musculoskeletal conditions (MSDs). Thematic analysis methods were used to analyse qualitative data collected from working individuals with RA, AS or PsA (n=22) that explored the extent to which measures of health status (EQ5D; SF6D) and capability (ICECAP-A) capture the impact on ability to work caused by RA, AS or PsA. Econometric methods were used to specify prediction models that included measures of health status, capability and presenteeism, using a sample of 542 working people with RA and AS. Results The first systematic review identified 24 self-report measures of presenteeism; all, except one measure were not underpinned by economic theory. The second systematic review identified 20 EE of WPIs for MSDs. Absenteeism was included in all studies (n=20); however, presenteeism was included in only four. The qualitative data confirmed measures of health status and capability had the ability to capture those aspects of RA, AS and PsA that impact an individual’s ability to work. The best performing prediction model used an OLS specification including SF6D, age and gender to predict presenteeism measured by the WPAI. Conclusion: The results suggest that HRQoL measures, specifically the SF6D, can be used to capture and predict levels of presenteeism caused by RA, AS and PsA.
APA, Harvard, Vancouver, ISO, and other styles
4

Sochart, David H. "The outcome of Charnley low-friction arthroplasty in young patients with particular reference to underlying disease process and acetabular wear." Thesis, University of Aberdeen, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.266921.

Full text
Abstract:
A consecutive series of 280 Charnley low-friction arthroplasties, performed between 1966 and 1978, on 192 patients, who were less than 40 years of age at the time of operation, were followed up for an average duration of 20.1 years. Patients were divided into four groups based on underlying disease process, and only three patients (5 hips) could not be traced. Patients with rheumatoid arthritis had significantly lower rates of acetabular component loosening, migration and revision (all p< 0.05), and patients with developmental dysplasia of the hip had the highest rates as well as a significantly higher rate of combined clinical and radiological component failure (p < 0.05). Patients with degenerative arthrosis had the highest rates of femoral implant loosening, revision and failure (all p < 0.05), and patients with ankylosing spondylitis and rheumatoid arthritis had the lowest. Age (< 30 years or 30 to 40 years at operation), gender, heterotopic ossification, hypertrophy of the femoral cortex at the tip of the prosthesis or development of changes in the medial femoral calcar were not associated with an increased risk of component failure or revision (all p > 0.05). The average annual rate of wear of revised components, in each of the four groups and the series as a whole, was significantly higher than the rate in surviving original components (p < 0.04), and the development of osteolysis, and increasing wear of the acetabular component were associated with failure and revision of both the acetabular and femoral components (both p < 0.01). Cox regression analysis confirmed that increasing average annual acetabular wear was the most significant factor determining the outcome of the arthroplasty (p < 0.001). For each additional millimetre of wear observed, the risk of component failure or revision in any one year increased significantly (p < 0.02). The 25-year survivorship of implants with an average acetabular wear rate of less than 0.1 mm/yr (117 arthroplasties) was greater than 90% but no arthroplasties with a rate in excess of 0.2 mm/yr survived 25 years, and only 40% survived 20 years.
APA, Harvard, Vancouver, ISO, and other styles
5

Jadon, Deepak. "Biomarkers of psoriatic arthritis phenotypes." Thesis, University of Bath, 2016. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.683546.

Full text
Abstract:
Background: Psoriatic arthritis (PsA) is a chronic heterogenous inflammatory arthritis with five phenotypes. The two least studied phenotypes are investigated in this thesis, including: psoriatic spondyloarthropathy (PsSpA) and psoriatic arthritis mutilans (PAM). The aims of this thesis were to determine the prevalence, clinical characteristics and radiographic characteristics of PsSpA and PAM in a cohort of PsA patients, and serum-soluble bone- turnover biomarkers of these phenotypes. Aims: Comparisons were made with PsA patients without axial disease (pPsA), and ankylosing spondylitis (AS) patients. Methods: A prospective single-centre cross-sectional study was conducted of PsA and AS patients. Serum on psoriasis-only patients (PsC) and healthy controls (HC) were also obtained. Multivariate clinical, radiographic, genetic and serum biomarker comparisons were made between these five groups of subjects. Results: The study enrolled 201 PsA and 201 AS patients, who were then reclassified as 118 PsSpA, 127 pPsA and 157 AS cases, alongside 200 PsC and 50 HC subjects. Several clinical biomarkers, imaging biomarkers, serum-soluble biomarkers and genetic biomarkers were identified that differentiate PsSpA from pPsA and AS. PsSpA affected a significant proportion of PsA patients, and was not a milder version of AS. PsSpA involvement was as disabling and clinically impactful as AS. PAM was found to be associated with PsSpA, and clinical biomarkers of PAM occurrence and radiographic progression were identified. Conclusions: In conclusion, this thesis indicates that PsSpA is on a spectrum of musculoskeletal disease, in between pPsA and AS; with PsSpA comprising a continuum itself, and with a phenotype expression related to disease duration. These findings may prompt the inception of an international-consensus classification system for PsSpA, for which there is a great clinical need. Given that PsSpA has its own discrete clinical and biomarker signature, its clinical management and research should be tailored from that of pPsA and AS. Ultimately this may further the effort for stratified and personalised medicine.
APA, Harvard, Vancouver, ISO, and other styles
6

Tiwana, Harmale Singh. "The immune response to gut bacteria in rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease." Thesis, King's College London (University of London), 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.430139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Madigan, Judith. "Antibody and T-Cell recognition of MHC- and mimicking tissue-peptides in autoimmune disease, particularly ankylosing spondylitis." Thesis, King's College London (University of London), 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.444151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hauser, Barbara. "Mechanism of bone loss in rheumatic diseases." Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/22823.

Full text
Abstract:
Osteoporosis and fragility fractures are recognized complications of inflammatory rheumatic diseases. This is thought to result from the effects of chronic inflammation, relative immobility and corticosteroid use. A rare syndrome of osteoporosis in a patient with coeliac disease has been described which results from production of neutralizing antibodies to the bone protective protein osteoprotegerin (OPG). The aim of my thesis is to evaluate prevalence and clinical predictors of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis (RA) and to investigate the role of OPG autoantibodies in the pathogenesis of osteoporosis in rheumatic diseases. In a retrospective cohort study, I found that the overall prevalence of osteoporosis in patients with RA was 29.9% which is in keeping with older reports that recorded a prevalence rate between 17% and 36%. In our contemporary cohort osteoporosis was significantly more common than in a gender and age matched control cohort (17.4%). Further analysis showed that only age and BMI were independent predictors of osteoporosis in RA. A predictive tool based on age and BMI was developed which had 91.4% sensitivity for the detection of osteoporosis in an independent RA population. I went on to screen for the presence of autoantibodies to OPG in patients with various rheumatic diseases. In a study of 75 patients with rheumatoid arthritis and 199 healthy controls OPG autoantibodies were detected in two controls (1%) compared with seven patients with RA (9.3%). The RA patients with detectable OPG antibodies had a longer disease duration, higher DAS28 scores and higher levels of the bone resorption marker CTX than RA patients who did not have autoantibodies. Purified IgG from patients with high levels of OPG antibodies blocked the ability of recombinant OPG to inhibit RANKL induced NFκB activation in a HEK293 cell based assay indicating that they were functional. In a further study of 134 patients with ankylosing spondylitis (AS), 16 patients (11.9%) had detectable OPG antibodies. The presence of OPG-Ab was independently associated with reduced hip bone mineral density and an increased risk of fractures in this population. In patients with a longer disease duration we have also observed that there was a higher discrepancy between spinal and hip BMD in OPG-Ab positive patients compared with OPG ab negative patients (p=0.003). In order to investigate if OPG antibodies affected measurement of serum RANKL concentrations as detected by ELISA using OPG as the capture reagent, I measured OPG ab and free RANKL concentrations in 55 rheumatic disease patients. Surprisingly there was a significant positive correlation between free RANKL and OPG Ab concentrations (r=0.430, p=0.001) which was the opposite to what I had expected. These findings reject the hypothesis that OPG ab block binding of synthetic OPG to RANKL in the ELISA. In conclusion, I have shown that osteoporosis is a common complication in RA and I have developed a new risk prediction tool for the use in clinical practice. I have also found that OPG antibodies are produced more commonly in patients with RA and AS than in healthy controls and that antibody levels correlate with bone resorption markers in RA and bone mineral density in AS patients. In vitro studies have shown that some OPG antibodies have functional effects on RANKL signalling. These findings raise the possibility that OPG antibodies may contribute to the pathogenesis of local and systemic bone loss in rheumatic diseases and signal the need to study the relationship between these antibodies and bone disease in large-scale longitudinal studies.
APA, Harvard, Vancouver, ISO, and other styles
9

Garpelin, Maja, and Emmelie Byhlin. "”JAG BLIR LIKSOM SOM FÖRR I TIDEN” : Upplevelse av hydroterapi hos personer med reumatisk sjukdom." Thesis, Mälardalens högskola, Akademin för hälsa, vård och välfärd, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-18641.

Full text
Abstract:
SAMMANFATTNING Hydroterapi har under en längre tid använts som behandlingsform, men det är brist på forskning inom området. Syftet med denna studie var att undersöka upplevelsen av hydroterapi hos personer med reumatisk sjukdom. En kvalitativ ansats anlades och enskilda semistrukturerade intervjuer användes. Deltagarna rekryterades genom bekvämlighetsurval via en kontakt på en reumatologklinik. Sex personer inkluderades: fem hade reumatoid artrit och en hade pelvospondylit. Resultatet tolkades med hjälp av en kvalitativ innehållsanalys, som visade på att deltagarna i denna studie var positivt inställda till hydroterapi. Deltagarna upplevde att hydroterapin ledde till minskad smärta, ökad rörlighet samt ett ökat välmående. Utöver de upplevda positiva effekterna återfanns även upplevda negativa effekter i form av träningsvärk och en ökad stelhet under sommaruppehållen. Det sociala samspel som uppstod i samband med hydroterapin upplevdes av de flesta deltagare ha haft positiv betydelse. Deltagarnas upplevelser kunde i diskussionen kopplas till operant och respondent inlärningsteori, där tänkbara konsekvenser och stimulin identifierades. Slutsatsen som drogs var att deltagarna upplevde hydroterapin som ett sätt att få tillbaka sin friska kropp genom att symtomen minskade. Då deltagarna upplevde att uppehåll orsakade försämring behövs hydroterapi som kontinuerlig behandlingsform för dem. Vidare forskning inom området bör fokuseras på enskilda patientgrupper samt inkludera ett större antal deltagare per patientgrupp. Nyckelord: hydroterapi, intervju, kvalitativ, pelvospondylit, reumatoid artrit.
APA, Harvard, Vancouver, ISO, and other styles
10

McHugh, Kirsty Anne. "The role of HLA-B27 in the pathogenesis of spondyloarthritis." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:d7df3150-9dcb-44fe-88a0-9fd54fe94b14.

Full text
Abstract:
The Human Leukocyte Antigen (HLA)-B27 is a Major Histocompability Complex (MHC) class I antigen that is strongly associated with development of a group of closely related arthritic diseases, collectively known as the spondyloarthropathies (SpA). However, the mechanism by which HLA-B27 confers this susceptibility is unclear. Studies have shown that HLA-B27 heavy chains can form classical heterotrimers associated with peptide and β2-microglobulin (B27HT), and also non-classical heavy chain homodimers (B27₂). B27₂ assemble intracellularly during maturation and are also expressed at the cell surface following endosomal recycling of B27HT. A pathogenic role for B27₂ has been proposed in two of the current theories of pathogenesis: the B27 homodimer theory and the B27 misfolding and UPR theory. Yet, determinations of the extent, distribution, and triggers of B27₂ expression, as well as the functional consequences of its receptor interactions in AS pathogenesis, have been hampered by the lack of a specific detection reagent. Therefore, to investigate the role of B27₂ in AS, we generated a novel antibody to B27₂ – HD6 – using phage display technology, which binds to in vitro refolded B27₂ but not B27HT complexes by ELISA. This thesis provides evidence that HD6-reactive molecules, which include B27₂, are expressed at the cell surface in both cell lines and in the context of a disease setting. Recognition is B27-specific and strongly correlated with the magnitude of B27 expression, which could account for the lack of staining in some cell subsets. Moreover, staining was comparable in cell lines expressing the disease-associated B*27:05 and the less disease-associated subtype B*27:09. In addition, I have shown cells expressing physiologic levels of B27, including EBV-transformed BCLs and AS patient PBMCs, are capable of expressing the HD6 epitope upon low pH treatment. Interestingly, these ‘acid-inducible HD6’ molecules were absent from cells lacking a functional PLC. Finally, I have shown that HD6-reactive molecules can derive from pre-existing folding B27 molecules at the cell surface, which may be inhibited by the addition of exogenous B27-binding peptides. These findings are consistent with a mechanism of pathogenesis involving the surface expression and recognition of B27₂ and/or other aberrantly folded forms of B27, as proposed in the homodimer theory. HD6 will be a powerful tool to address the potential pathogenic role of B27₂ in SpA and may additionally have therapeutic potential.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Autoimmune arthritis; Ankylosing spondylitis"

1

H, Mielants, and Veys E. M, eds. Spondyloarthropathies, involvement of the gut: Proceedings of the First Conference on Spondyloarthropathies, Involvement of the Gut, Ghent, 10-13 September 1986. Amsterdam: Excerpta Medica, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sieper, Joachim. Ankylosing spondylitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0113.

Full text
Abstract:
Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly of the sacroiliac joint (SIJ) and the spine. It starts normally in the second decade of life and has a slight male predominance. The prevalence is between 0.2 and 0.8% and is strongly dependent on the prevalence of HLA B27 in a given population. For the diagnosis of AS, the presence of radiographic sacroiliitis is mandatory. However, radiographs do not detect active inflammation but only structural bony damage. Most recently new classification criteria for axial spondyloarthritis (SpA) have been developed by the Assessement of Spondylo-Arthritis international Society (ASAS) which cover AS but also the earlier form of non-radiographic axial SpA. MRI has become an important new tool for the detection of subchondral bone marrow inflammation in SIJ and spine and has become increasingly important for an early diagnosis. HLA B27 plays a central role in the pathogenesis but its exact interaction with the immune system has not yet been clarified. Besides pain and stiffness in the axial skeleton patients suffer also from periods of peripheral arthritis, enthesitis, and uveitis. New bone formation as a reaction to inflammation and subsequent ankylosis of the spine determine long-term outcome in a subgroup of patients. Currently only non-steroidal anti-inflammatory drugs (NSAIDs) and tumour necrosis factor (TNF) blockers have been proven to be effective in the medical treatment of axial SpA, and international ASAS recommendations for the structured management of axial SpA have been published based on these two types of drugs. Conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate are not effective.
APA, Harvard, Vancouver, ISO, and other styles
3

Siebert, Stefan, Sengupta Raj, and Alexander Tsoukas. What are axial spondyloarthritis and ankylosing spondylitis? Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198755296.003.0001.

Full text
Abstract:
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting mainly the sacroiliac joints and spine, resulting in pain, stiffness, and reduced movement. AS has a major negative impact on patients’ quality of life. AS is part of a larger group of related spondyloarthritis (SpA) conditions and patients with AS often have extra-articular manifestations of these conditions. Over the past decade, there have been major advances in the understanding of the genetics and pathophysiology of the disease. Advances in imaging have allowed patients to be diagnosed without having to develop the radiographic structural damage that characterize AS, resulting in the concept of axial spondyloarthritis (axSpA). Together with the development of highly effective TNF inhibitors, these advances have transformed the management and outlook of patients with this condition. It is hoped that further advances in diagnosis, assessment and treatment of axSpA will lead to further progress in future.
APA, Harvard, Vancouver, ISO, and other styles
4

Wiffen, Philip, Marc Mitchell, Melanie Snelling, and Nicola Stoner. Therapy-related issues: musculoskeletal. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198735823.003.0024.

Full text
Abstract:
This chapter outlines information relevant to clinical pharmacists related to musculoskeletal diseases and is loosely based on the British National Formulary, Chapter 10. In particular, this chapter covers rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoarthritis, osteoporosis, and gout.
APA, Harvard, Vancouver, ISO, and other styles
5

A, Ebringer, and Shipley Michael, eds. Pathogenesis of ankylosing spondylitis and rheumatoid arthritis: Proceedings of the second international symposium held at the Middlesex Hospital, 14-15 April 1987. London: Baillière Tindall, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Berry, Colin. Bone, joint, and connective tissue disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198719410.003.0009.

Full text
Abstract:
This chapter describes the anaesthetic management of the patient with those musculoskeletal disorders which are relevant to anaesthetic practice. Topics covered include rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic sclerosis, scoliosis, and achondroplasia. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described.
APA, Harvard, Vancouver, ISO, and other styles
7

Berry, Colin. Bone, joint, and connective tissue disorders. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198719410.003.0009_update_001.

Full text
Abstract:
This chapter describes the anaesthetic management of the patient with those musculoskeletal disorders which are relevant to anaesthetic practice. Topics covered include rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic sclerosis, scoliosis, and achondroplasia. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described.
APA, Harvard, Vancouver, ISO, and other styles
8

Khan, Muhammad Asim. Clinical features. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198734444.003.0011.

Full text
Abstract:
The leading chronic progressive inflammatory disease of the sacroiliac joints and the spinal column, traditionally known as ankylosing spondylitis (AS), is a relatively common but insidious rheumatic disease that can cause progressive limitation of physical function. It is a prototype of related forms of arthritis, grouped under the term spondyloarthritis that is subdivided into predominantly axial and predominantly peripheral forms. This chapter details the clinical features of axial spondyloarthritis, a term that encompasses ankylosing spondylitis. There is a predilection for the inflammation to affect sites where the tendons and ligaments attach to the bones (entheses) and can result in gradual and progressive spinal ankylosis, with resultant physical deformity. The disease may present with a wide spectrum of clinical features, both articular and extra-articular, and can be difficult to diagnose in early stages.
APA, Harvard, Vancouver, ISO, and other styles
9

Kulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. Rheumatology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0018.

Full text
Abstract:
This chapter focuses on some of the most influential clinical trials in rheumatology, with special focus on rheumatoid arthritis, ankylosing spondylitis, and gout. Today, there are clear criteria established for the clinical manifestations of rheumatic diseases, but there is still a long way to go in terms of establishing a clear understanding of their pathogenesis.
APA, Harvard, Vancouver, ISO, and other styles
10

Tillett, William, and Neil McHugh. Plain radiography. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0016.

Full text
Abstract:
Psoriatic arthritis is a destructive inflammatory arthritis that can affect the peripheral and axial skeleton of patients with psoriasis. Plain radiography has formed an important part in defining psoriatic arthritis as a distinct clinical entity, from early work reporting on distinguishing features to more recent inclusion of osteoproliferation in the CASPAR classification criteria. Plain radiography is accessible, inexpensive and remains the standard measure of assessing damage in inflammatory arthritis. Originally considered a benign disease psoriatic arthritis is now recognised to be destructive and progressive, though not as aggressive as rheumatoid arthritis. Peripheral joint damage is characterised by erosions, joint space narrowing, osteoproliferation, osteolysis and ankylosis. Approximately twenty percent of patients have erosive disease at diagnosis progressing to approximately half of all patients by three years disease duration. In its most severe form, psoriatic arthritis mutilans, digits become shortened from gross bone resorption (osteolyisis) leading to severe functional impairment and disability. Spondyloarthritis may affect between 25-70% of patients with PsA. The radiographic features of Psoriatic Spondyloarthritis differ from Ankylosing Spondylitis, in that sacroiliitis is often asymmetrical and less severe, the cervical spine is frequently involved and syndesmophytes are asymmetrical and para-marginal. Overall radiographic features are less severe than ankylosing spondylitis. The natural history of both peripheral and axial radiographic damage in psoriatic arthritis in the modern era of early diagnosis, tight disease control and biologic drugs has yet to be established.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Autoimmune arthritis; Ankylosing spondylitis"

1

White, Douglas H. N. "Rheumatoid Arthritis and Ankylosing Spondylitis." In Principles of Osteoimmunology, 169–95. Vienna: Springer Vienna, 2012. http://dx.doi.org/10.1007/978-3-7091-0520-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Abdulkhaliq, Altaf. "Bones and Rheumatology." In Skills in Rheumatology, 209–39. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8323-0_10.

Full text
Abstract:
AbstractBone is a target tissue in many inflammatory diseases including rheumatic diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and psoriatic arthritis.
APA, Harvard, Vancouver, ISO, and other styles
3

van der Heijde, Dèsirèe. "Study Design and End Points in Ankylosing Spondylitis Clinical Trials." In Clinical Trials in Rheumatoid Arthritis and Osteoarthritis, 69–79. London: Springer London, 2008. http://dx.doi.org/10.1007/978-1-84628-742-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Al-ghamdi, Abdullah A. "Eye and Rheumatology." In Skills in Rheumatology, 419–28. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8323-0_19.

Full text
Abstract:
AbstractThe ocular involvement in rheumatology can be in a wide variety; it ranges from simple episcleritis to significant visual loss. Early detection followed by appropriate management can reserve vision. Ophthalmic involvement may occur in all of the rheumatic disorders. Ocular manifestation may be a presenting sign in some disorders, as in juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and Sjogren’s syndrome (SjS), or can be a presenting sign with the systemic involvement as in systemic lupus erythematosus (SLE), polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), and systemic sclerosis. Thus ocular manifestations in rheumatologic diseases (Table 19.1) can be the link in approaching the diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
5

Lakomek, H. J., and M. Schwochau. "Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA): Improved Diagnosis and Attempts Towards the Molecular Analysis of Etiology and Pathogenesis of These Systemic Rheumatic Diseases." In Molecular and Cell Biology of Autoantibodies and Autoimmunity. Abstracts, 41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-46681-6_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yong, Terwa, and Alice Hoftman. "Rheumatologic Disorders." In General Pediatrics Board Review, 290–300. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190848712.003.0014.

Full text
Abstract:
This chapter reviews the pediatric rheumatologic disorders that present to the general practitioner in settings involving regular or urgent care. The clinical scenarios presented, which are followed by a question-and-answer format review, encompass common and rare rheumatologic conditions. The conditions reviewed include such topics as Henoch-Schönlein purpura, Kawasaki disease, acute rheumatic fever, juvenile idiopathic arthritis, ankylosing spondylitis, postinfectious arthritis, various causes of autoimmune and nonautoimmune musculoskeletal joint pain (including some genetic connective tissue disorders and lupus). Furthermore, some of the salient laboratory testing specific to rheumatologic illnesses is covered in relation to these conditions.
APA, Harvard, Vancouver, ISO, and other styles
7

"Rheumatology." In Oxford Handbook for Medical School, edited by Kapil Sugand, Miriam Berry, Imran Yusuf, Aisha Janjua, Chris Bird, David Metcalfe, Harveer Dev, et al., 609–20. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780199681907.003.0031.

Full text
Abstract:
Chapter 31 gives an overview of rheumatology, the study of rheumatic conditions which can involve the joints, soft tissues, and bones and also comprises connective tissue disorders, vasculitides, and a number of autoimmune conditions. The chapter outlines patterns of rheumatological disease (e.g. mono-, oligo-, and polyarthropathies), symmetrical versus asymmetrical presentations of disease, and explains how to try and differentiate between inflammatory and non-inflammatory disorders. The chapter provides information on common drug treatments, including dangerous side effects from improperly prescribed methotrexate. Advice is given on history taking and detailed hand examination, with clinical signs of rheumatoid arthritis: Swan neck deformity, Boutonniere’s deformity, Z deformity of thumb, Bouchard’s nodes (proximal interphalangeal joint), Heberden’s nodes (distal interphalangeal joint, first metacarpophalangeal joint), finger ulnar deviation (metacarpophalangeal joint), and wrist radial deviation and subluxation. The most common rheumatological disorders are discussed, including rheumatoid arthritis, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, gout, and osteoporosis (including the ‘MESSAGE’ mnemonic for osteoporosis risk factors). The Chapel Hill classification for vasculitides is also covered.
APA, Harvard, Vancouver, ISO, and other styles
8

Bowers, Emily, and M. Kristen Demoruelle. "Autoimmune diseases: Sex and gender evidence in rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis." In How Sex and Gender Impact Clinical Practice, 53–73. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-12-816569-0.00004-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Brower, Anne C., and Donald J. Flemming. "Ankylosing Spondylitis." In Arthritis in Black and White, 226–42. Elsevier, 2012. http://dx.doi.org/10.1016/b978-1-4160-5595-2.00012-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cai, Qing, and Qiang Tong. "Inflammatory Arthritis: Ankylosing Spondylitis." In Encyclopedia of Bone Biology, 689–96. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-801238-3.11559-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Autoimmune arthritis; Ankylosing spondylitis"

1

Curcic, ZA. "SAT0007 Ankylosing spondylitis initiated as a reactive arthritis." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Aykut, M., B. Cakit, E. Mert, S. Aslan, E. Sahingoz, H. Genc, FF Ayhan, and A. Karagoz. "AB0255 Evaluation of kinesiophobia in patients with rheumatoid arthritis and ankylosing spondylitis." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Robles, Bryan-Josué Flores, Valvanera Pinillos, Angel Elena-Ibáñez, Eztizen Labrador-Sánchez, Leticia Merino-Meléndez, Juan Antonio López-Martín, and Enrique Ramalle-Gómara. "THU0378 COEXISTENCE OF ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS (ANALYSIS OF 73 CASES)." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rasmussen, S. E., C. Brock, A. Mohr Drewes, and M. Pfeiffer Jensen. "SAT0298 Transcutaneous vagus nerve stimulation in patients with psoriatic arthritis or ankylosing spondylitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4731.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mulholland, Orlagh, and Hilary Mckee. "FRI0455 USE OF SECUKINUMAB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS….REAL WORLD DATA." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ogdie, A., K. de Vlam, I. B. McInnes, P. J. Mease, P. Baer, T. Lukic, K. Kwok, C. Wang, M. A. Hsu, and A. Maniccia. "SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lara, MJ Morales, L. Yunquera Romero, C. Ortega de la Cruz, P. Conesa Zamora, C. González Pérez-Crespo, and I. Muñoz Castillo. "PS-084 Negative results asocciated with TNF antagonists in rheumatoid arthritis and ankylosing spondylitis." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grisar, J., M. Aringer, K. Redlich, PM Bernecker, W. Wolozcszuk, JS Smolen, and P. Pietschmann. "SAT0035 Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption and differ with regard to bone formation." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.387.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Konsta, M., MT Nurmohamed, A. Iliopoulos, JC van Denderen, I. Visman, PP Sfikakis, and IE van der Horst-Bruinsma. "FRI0455 Radiographic progression of hip arthritis in patients with ankylosing spondylitis treated with tnf inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Konsta, M., MT Nurmohamed, A. Iliopoulos, JC van Denderen, I. Visman, PP Sfikakis, and IE van der Horst-Bruinsma. "SAT0415 High prevalance of hip arthritis in patients with ankylosing spondylitis treated with tnf inhibitors." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.6844.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Autoimmune arthritis; Ankylosing spondylitis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography